Last reviewed · How we verify

Ropivacaine 0.2% for PENG Block

Poznan University of Medical Sciences · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. Used for Regional anesthesia via PENG block for hip surgery perioperative analgesia.

At a glance

Generic nameRopivacaine 0.2% for PENG Block
SponsorPoznan University of Medical Sciences
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. This prevents depolarization and action potential generation in sensory and motor nerves. When administered via PENG (Pericapsular Nerve Group) block, it anesthetizes the nerves supplying the hip joint capsule, providing perioperative analgesia for hip surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: